Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 15242866.
- Also identified by PMC identifier 1754871.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Anti-TNFalpha therapy may have associated risks of serious infection, congestive heart failure, malignancy, and multiple sclerosis. The magnitude of these risks is difficult to assess. This article reviews publications on the current knowledge about the safety of these agents.
Medical subject headings
- Antibodies, Monoclonal
- Antirheumatic Agents
- Arthritis, Rheumatoid
- Immunoglobulin G
- Tumor Necrosis Factor-alpha